
Schott Pharma Invests in Sterile Cartridge Production
Schott Pharma is investing more than €100 million in its existing site in Lukácsháza, Hungary, to expand its capacity for sterile ready-to-use (RTU) cartridges.
Schott Pharma is investing more than €100 million in its existing site in Lukácsháza, Hungary, to expand its capacity for sterile ready-to-use (RTU) cartridges.
In a move to triple its production of glass and polymer syringes for the US market by 2030, Germany’s Schott Pharma announced plans to build its first US facility to manufacture prefillable polymer syringes that meet the need for deep-cold storage and transportation of mRNA medications.